MDMA-Assisted Psychotherapy: Essential Insights for Pharmacists
Melbourne, Australia; May 22, 2024—Researchers from Monash University have published a comprehensive review detailing critical information pharmacists need to know regarding 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy, especially following its approval for treating post-traumatic stress disorder (PTSD) in Australia.
-
Cytochrome P450 2D6 Interaction: MDMA is metabolized by the CYP2D6 enzyme; co-administration with CYP2D6 inhibitors can elevate MDMA plasma concentrations, increasing the risk of adverse effects.
-
Serotonergic Medications: Concurrent use of selective serotonin reuptake inhibitors (SSRIs) with MDMA may reduce therapeutic efficacy due to serotonin transporter inhibition.
-
Monoamine Oxidase Inhibitors (MAOIs): Combining MDMA with MAOIs poses a significant risk of serotonin toxicity.
- Multiple MDMA Administrations: Some therapy protocols include a supplemental MDMA dose, potentially heightening cardiovascular and neurotoxic risks.
- Cardiovascular Risks: MDMA can increase blood pressure and heart rate, posing concerns for patients with pre-existing cardiovascular conditions.
- Other Drug Interactions: Caffeine, alcohol, over-the-counter medicines, serotonin precursors (such as tryptophan and 5-HTP) may interact with MDMA, necessitating careful medication history assessments.
Introduction
On July 1, 2023, the Therapeutic Goods Administration (TGA) in Australia approved the use of MDMA-assisted psychotherapy for treating PTSD. This groundbreaking decision underscores the importance of pharmacists understanding MDMA's pharmacology, potential drug interactions, and their role in patient management during therapy.
Pharmacokinetics and Drug Interactions
Cytochrome P450 2D6 (CYP2D6) Metabolism
MDMA undergoes primary metabolism via CYP2D6. Inhibitors of CYP2D6 (such as fluoxetine, paroxetine, and bupropion) can elevate MDMA plasma concentrations, increasing the risk of adverse effects, including neurotoxicity and cardiovascular strain.
Serotonergic Medications
- Selective Serotonin Reuptake Inhibitors (SSRIs) inhibit the serotonin transporter, reducing MDMA’s ability to enter presynaptic neurons, dampening its psychoactive effects.
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) exhibit similar interactions, leading to MDMA withdrawal prior to therapy to ensure full therapeutic efficacy.
Monoamine Oxidase Inhibitors (MAOIs) and Serotonin Toxicity
- MAOIs (e.g., phenelzine, tranylcypromine, moclobemide) significantly increase the risk of serotonin syndromewhen combined with MDMA.
- This combination is contraindicated due to potential life-threatening hyperthermia, neuromuscular abnormalities, and autonomic instability.
Multiple MDMA Administrations in a Session
- Some therapy protocols involve a second, lower dose of MDMA during a session to extend therapeutic effects.
- While beneficial for psychotherapy, repeated MDMA exposure within a short period may increase cardiovascular stress and neurotoxicity risks.
- Patients with hypertension or other cardiovascular conditions require careful monitoring due to MDMA’s stimulant effects.
Cardiovascular Risks of MDMA Therapy
- MDMA induces sympathomimetic effects, leading to increased heart rate and blood pressure.
- Patients with pre-existing heart disease, hypertension, or arrhythmias may experience elevated cardiovascular risks.
- Baseline cardiovascular screening is recommended before initiating MDMA-assisted therapy.
Interactions with Other Substances
Tryptophan and 5-HTP (5-Hydroxytryptophan)
- Tryptophan and 5-HTP are serotonin precursors that may exacerbate serotonin syndrome risk when combined with MDMA.
- Patients should avoid using these supplements before and after MDMA therapy to reduce serotonergic overstimulation.
LSD and Other Psychedelics
- LSD (lysergic acid diethylamide) and psilocybin are serotonergic substances that are sometimes taken alongside MDMA.
- Anecdotal and observational data suggest that combining MDMA with LSD or psilocybin may buffer against challenging experiences and enhance positive experiences during the psychedelic trip.
- MDMA has been shown to prolong the effects of LSD, likely due to higher plasma concentrations and a longer elimination half-life of LSD, which is explained by CYP2D6 inhibition by MDMA.
Role of Pharmacists in MDMA-Assisted Psychotherapy
Medication History and Management
Pharmacists play a crucial role in collecting comprehensive medication histories to identify potential drug interactions. This includes advising on the safe discontinuation of contraindicated medications and monitoring for any adverse effects during therapy.
Patient Education
Educating patients about the importance of disclosing all substances they are taking, including over-the-counter drugs and supplements, is vital to ensure safety and efficacy during MDMA-assisted psychotherapy.
Interdisciplinary Collaboration
Pharmacists should collaborate closely with other healthcare professionals to develop and implement protocols that minimize risks associated with drug interactions in MDMA-assisted psychotherapy.
Conclusion
As MDMA-assisted psychotherapy emerges as a treatment for PTSD, pharmacists must be well-informed about MDMA's pharmacological properties, potential drug interactions, and their role in patient care. By doing so, they can help optimize therapeutic outcomes and ensure patient safety in this innovative treatment approach.
Reference